Skip to main content
TipRanks
Go Ultimate75% OFF

Nath Bio-Genes (India) Ltd. (NATHBIOGEN) AI Stock Analysis

3 Followers
IN:NATHBIOGEN

Nath Bio-Genes (India) Ltd.

(NSE:NATHBIOGEN)

Select Model
Rating:66Neutral
Price Target:INR 151.00â–²(6.00% Upside)
Action:reiterated
Date:11/12/26

The score is supported by strong balance-sheet quality, low leverage, revenue growth, and attractive valuation. These strengths are materially offset by negative cash flow and mixed-to-weak technical trends, resulting in a moderately positive overall assessment.

Positive Factors
Seed-focused agricultural business modelThe company operates across plant breeding, seed production, processing, and marketing, giving it an integrated position in the agricultural-inputs value chain. Its proprietary and third-party seed portfolio can support continued participation in domestic farming demand through established distribution channels.
Negative Factors
Weak and volatile cash conversionNegative operating and free cash flow despite positive earnings raises concern about the durability of reported profits and near-term funding flexibility. Persistent variability can increase reliance on working-capital management or external financing, limiting the cash available for reinvestment and shareholder returns.

Nath Bio-Genes (India) Ltd. (NATHBIOGEN) vs. iShares MSCI India ETF (INDA)

-30%-20%-10%0%10%20%IN:NATHBIOGEN-11.77%INDA-5.86%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 2.69B
Dividend Yield
1.40%
Average Volume (3M)
1,005
Price to Earnings (P/E)
7.7
Beta (1Y)
1.02
Revenue Growth
21.02%
EPS Growth
-3.13%
Country
India
Employees
452
Sector
General
Sector Strength
55
Industry
Agricultural Inputs

Nath Bio-Genes (India) Ltd. Business Overview & Revenue Model

Company Description

Nath Bio-Genes (India) Limited is dedicated to the development, preparation, and worldwide distribution of both hybrid and genetically modified (GM) seeds, catering to demand within India and internationally. Its business operations are organized int...

How the Company Makes Money

Nath Bio-Genes primarily makes money by selling seeds to the domestic agricultural market through its marketing and distribution network. Its main revenue stream is the sale of proprietary and third-party seeds (typically including hybrid seeds, wher...

Nath Bio-Genes (India) Ltd. Financial Statement Overview

Summary

Revenue growth, recovering profitability, strong equity, and low leverage support the score. However, sharply negative operating and free cash flow indicate significant working-capital strain.

Income Statement

72Positive

Balance Sheet

85Very Positive

Cash Flow

45Neutral
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue4.90B4.45B3.65B2.48B3.01B2.78B
Gross Profit2.12B2.04B2.29B1.03B1.67B1.54B
EBITDA613.59M662.56M497.98M536.39M488.91M-497.06M
Net Income386.75M416.30M386.00M396.19M350.11M-673.38M
Balance Sheet
Total Assets010.97B10.26B8.80B7.93B7.42B
Cash, Cash Equivalents and Short-Term Investments759.95M759.95M888.99M774.10M379.90M41.68M
Total Debt01.39B1.23B1.10B1.05B929.59M
Total Liabilities-6.80B4.17B3.82B2.70B2.20B2.00B
Stockholders Equity6.80B6.80B6.44B6.10B5.73B5.42B
Cash Flow
Free Cash Flow-1.10B-250.40M96.61M478.18M358.18M-39.70M
Operating Cash Flow-1.09B-220.35M175.81M745.94M383.67M170.46M
Investing Cash Flow-11.48M-30.69M-39.62M-274.01M-28.84M-198.66M
Financing Cash Flow216.74M122.00M-21.30M-77.78M-16.68M-222.27M

Nath Bio-Genes (India) Ltd. Technical Analysis

Technical Analysis SentimentPositive
Last Price142.45

Price Trends

50DMA140.87Positive
100DMA149.73Negative
200DMA152.30Negative

Market Momentum

MACD-0.08Negative
RSI60.18Neutral
STOCH69.77Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:NATHBIOGEN, the sentiment is Positive. The current price of 142.45 is above the 20-day moving average (MA) of 134.84, above the 50-day MA of 140.87, and below the 200-day MA of 152.30, indicating a neutral trend. The MACD of -0.08 indicates Negative momentum. The RSI at 60.18 is Neutral, neither overbought nor oversold. The STOCH value of 69.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:NATHBIOGEN.

Nath Bio-Genes (India) Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

IN:NATHBIOGEN against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:DHANUKAIN:DHANUKA73OutperformINR 40.27B14.56―0.22%-0.06%0.75%
IN:SHARDACROPIN:SHARDACROP71OutperformINR 65.69B10.22―2.06%17.28%42.45%
IN:INSECTICIDIN:INSECTICID66NeutralINR 15.74B12.58―0.92%1.26%-16.43%
IN:NATHBIOGENIN:NATHBIOGEN66NeutralINR 2.71B7.70―1.40%21.02%-3.13%
IN:RALLISIN:RALLIS63NeutralINR 36.79B18.71―1.59%6.82%11.93%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
IN:IPLIN:IPL55NeutralINR 13.73B14.38―0.63%2.89%-9.47%

* General Sector Average

Performance Comparison

-20%0%20%40%IN:NATHBIOGENIN:DHANUKAIN:INSECTICIDIN:IPLIN:RALLISIN:SHARDACROPDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:NATHBIOGEN and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:NATHBIOGENNath Bio-Genes (India) Ltd.142.45-21.33-13.02%
IN:DHANUKADhanuka Agritech Limited903.45-365.10-28.78%
IN:INSECTICIDInsecticides (India) Limited541.00-128.01-19.13%
IN:IPLIndia Pesticides Ltd.119.20-59.68-33.37%
IN:RALLISRallis India Limited189.20-57.98-23.46%
IN:SHARDACROPSharda Cropchem Ltd.728.15-53.22-6.81%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 12, 2026